Akero Therapeutics Highlights Efruxifermin at AASLD 2024
Akero Therapeutics' Upcoming Presentations at AASLD 2024
In an exciting announcement, Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company renowned for developing innovative treatments for serious metabolic diseases, is set to present new findings at the 75th Annual American Association for the Study of Liver Diseases (AASLD) The Liver Meeting for 2024. Taking place in San Diego, from November 15-19, 2024, these presentations will provide significant insights into the efficacy of efruxifermin (EFX), the company's lead product candidate.
Highlights from the HARMONY Study
The presentations will feature data collected from the 96-week Phase 2b HARMONY study, which examined the effects of efruxifermin on patients suffering from metabolic dysfunction-associated steatohepatitis (MASH), specifically those in fibrosis stage 2 or 3. The findings aim to demonstrate not only the efficacy in improving liver fibrosis but also the safety of EFX in this patient population.
Key Presentation Details
One of the prominent presentations titled "Efruxifermin Significantly Improved Liver Fibrosis at Week 96 in the HARMONY Study Across Subgroups and Improvements Were Associated With Changes in Biomarkers" will be delivered by Dr. Mazen Noureddin, a well-respected professor of medicine at Houston Methodist Hospital. This oral session is scheduled for November 17, 2024, from 2:00 PM to 2:15 PM PST.
Late-Breaking Poster Presentations
In addition, Dr. Noureddin will also lead two late-breaking poster presentations on November 18, 2024. The first poster is titled "Efruxifermin significantly reduced the proportion of subjects with at-risk MASH and led to near-complete histological disease reversal at week 96 in the HARMONY study," showcasing the remarkable impacts of EFX treatment. The second poster will explore "AI and digital-based pathology corroborate reduction in fibrosis observed by conventional pathology with efruxifermin treatment of patients with F2-F3 MASH in the HARMONY study." These presentations emphasize a comprehensive analysis using advanced digital tools, reinforcing the credibility of the study results.
About Akero Therapeutics
Akero Therapeutics is at the forefront of clinical development for revolutionary treatments aimed at serious metabolic diseases. They continue to push the boundaries with their lead product candidate, EFX, which is currently subject to rigorous scrutiny in ongoing trials. The SYMMETRY study is a pivotal 96-week Phase 2b clinical trial focusing on patients with compensated cirrhosis due to MASH (F4 fibrosis). Moreover, the company is also conducting three expansive Phase 3 clinical trials under the SYNCHRONY program, which focus on patients experiencing pre-cirrhotic MASH or compensated cirrhosis.
The Path Forward for MASH Treatments
The advancements achieved through previous Phase 2 trials, like the HARMONY study, pave the way for a brighter future in managing MASH conditions. The insights derived from comprehensive research not only contribute to treatment efficacy but also open doors for new therapeutic avenues explored through sophisticated methods such as AI in pathology.
Company Vision and Commitment
Headquartered in South San Francisco, Akero Therapeutics is dedicated to addressing high unmet medical needs with a patient-centric approach. Their commitment is evident in their ongoing research, which seeks to transform the landscape of treatment for patients suffering from metabolic diseases, particularly regarding liver health and development.
Frequently Asked Questions
What is efruxifermin?
Efruxifermin is a therapeutic candidate developed by Akero Therapeutics aimed at treating metabolic dysfunction-associated steatohepatitis (MASH).
When will Akero present its findings at AASLD 2024?
Akero will present findings during the AASLD 2024 conference, scheduled from November 15-19, 2024, with specific presentations on November 17 and 18.
Who is presenting the data on efruxifermin?
Dr. Mazen Noureddin will present the data, showcasing his expertise as a professor of medicine at Houston Methodist Hospital.
What is the significance of the HARMONY study?
The HARMONY study is crucial as it evaluates the effectiveness of efruxifermin in improving liver fibrosis in patients with MASH, demonstrating potential for significant clinical impact.
How can I learn more about Akero Therapeutics?
You can find more information about Akero Therapeutics and their ongoing studies by visiting their official website at akerotx.com or following them on their social media platforms.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Navigating Your 401(k): Stocks vs. Bonds Insights
- Kirkland's Growth Potential Boosted by Strategic Partnerships
- LaSalle Investment Management Achieves Exceptional ESG Ratings
- Exploring the Growing Autoclave Market and Its Innovations
- Kevin McCarthy Joins Anivive Lifesciences Board to Combat Disease
- Immersion Investments Calls for Strategic Change at Potbelly
- Corporate Deposit Returns Decline: Impact on Financial Stocks
- HARIBO Enchants with Unique Float for Thanksgiving Parade
- Community Heritage Financial, Inc. Declares Q3 2024 Dividend
- Jim Kaitz Retires as AFP President; Pat Culkin Ascends
Recent Articles
- Incredibles and Magnolia Bakery Join Forces in Sweet Treats
- Marquette National Corporation Announces $0.28 Dividend Payment
- Arvinas Gears Up for Q3 2024 Financial Results Overview
- Endeavour Silver's Terronera Project Achieves Major Milestones
- Pandora's Ambitious Share Buyback Program Explained
- Nicholas Wealth Boosts FIAX ETF with Significant Growth in AUM
- BJ's Wholesale Club Plans Earnings Call for Q3 Fiscal 2024
- Viad Corp's Exciting Shift to Focused Hospitality Ventures
- Great Ajax Corp. Reports Q3 2024 Financial Highlights
- Oscar Health's 2025 Vision for Affordable Health Insurance
- Boeing Plans Asset Sales to Strengthen Financial Stability
- Ferguson Enterprises Announces Upcoming Quarterly Dividend Payments
- Friedrich Vorwerk Sees Share Surge With Positive Guidance Shift
- Blackstone Secured Lending Fund Prepares for Q3 Investor Call
- Can the S&P 500 Continue Its Impressive Rally Amid Risks?
- Citgo Creditors Challenge Elliott's Bid, Seek New Offers
- Hyperscale Data Celebrates Sustainable Growth with Dividends
- Challenges Faced by U.S. Farmers Amid Harvest Surge
- Parsons Corporation Strengthens Its Engineering Portfolio
- Qatar Faces Challenges in LNG Market Amid Growing Competition
- Barclays Predicts Growth for Alaska Air Following Merger Gains
- Citi Optimistic on Ally Financial's Growth Potential Ahead
- Citi's Neutral Rating on Fifth Third: Analysis and Insights
- Citi's Neutral Stance Highlights Columbia Sportswear's Trends
- Citi Highlights Strong Potential for Huntington Bancshares Welcome
- Coalition of Survivors Calls for Unity Against Trump’s Actions
- Citi Raises Comerica Stock Target Amid Optimistic Outlook
- Canada Nickel Company Welcomes Julian Ovens to Board
- Enhancing Legal Funding: Legal-Bay's New Website and Services
- Elme Communities Faces Market Challenges Amid Strategic Changes
- Exploring Islamic Finance: A Path to Global Sustainability
- Tractor Supply Company's Stock Outlook Brightens Significantly
- Jefferies Boosts Netflix Price Target Amid Subscriber Growth
- Parsons Corporation Expands Infrastructure Footprint with BCC
- Septerna Moves Forward with Major Share IPO Announcement
- Venu Holding Corp Sets IPO with 1M Shares at $10 Each
- Goldman Sachs Projects Low S&P 500 Returns for Coming Decade
- Analysts Doubt Apple Intelligence Will Enhance iPhone Sales
- Rising Challenges for GM and Ford Amidst EV Pricing Pressures
- Earnings Highlights: Key Stocks Shaping the Financial Landscape
- Cisco's Innovations and Analyst Upgrades Spark Renewed Interest
- Handheld 3D Scanners Expected to Surpass $2.55 Billion by 2032
- Projected Growth of Gas Pressure Regulator Market to 2034
- BioNTech's Upcoming Q3 2024 Financial Results Announcement
- Hyperscale Data Maintains Impressive Dividend Record
- Parsons Corporation Expands Its Footprint with BCC Engineering Deal
- Discovering Scandinavian Tobacco's Strategic Share Buyback Actions
- Bilibili Inc. Offers Unique Repurchase Rights for 2026 Notes
- Sila Realty Trust, Inc.'s Key Updates on Q3 2024 Earnings
- Revyse Secures $1 Million Investment, Innovates Vendor Management